Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Operating Leases: 2019-2024

Historic Operating Leases for RedHill Biopharma (RDHL) over the last 6 years, with Dec 2024 value amounting to $3,000.

  • RedHill Biopharma's Operating Leases fell 41.85% to $214,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $214,000, marking a year-over-year decrease of 41.85%. This contributed to the annual value of $3,000 for FY2024, which is 99.34% down from last year.
  • As of FY2024, RedHill Biopharma's Operating Leases stood at $3,000, which was down 99.34% from $455,000 recorded in FY2023.
  • Over the past 5 years, RedHill Biopharma's Operating Leases peaked at $6.4 million during FY2022, and registered a low of $3,000 during FY2024.
  • Over the past 3 years, RedHill Biopharma's median Operating Leases value was $455,000 (recorded in 2023), while the average stood at $2.3 million.
  • In the last 5 years, RedHill Biopharma's Operating Leases surged by 150.31% in 2022 and then tumbled by 99.34% in 2024.
  • Yearly analysis of 5 years shows RedHill Biopharma's Operating Leases stood at $3.8 million in 2020, then crashed by 32.39% to $2.6 million in 2021, then soared by 150.31% to $6.4 million in 2022, then plummeted by 92.94% to $455,000 in 2023, then crashed by 99.34% to $3,000 in 2024.